Evogene Highlights AI Innovations in Pharma and Agriculture at H.C. Wainwright Conference

Evogene Emphasizes AI-Driven Innovations in Pharmaceutical and Agricultural Development

Evogene Ltd., a frontrunner in computational biology and chemistry, showcases its commitment to advancing drug and agricultural product development through innovative technology. During the H.C. Wainwright 27th Annual Global Investment Conference in New York, President and CEO Ofer Haviv emphasizes the strategic importance of the company's proprietary generative AI tech-engine, ChemPass AI. This platform is engineered to discover and optimize small molecules, a crucial step in the pharmaceutical and agricultural sectors where time and resource efficiency can significantly impact success rates. The presentation, set for September 10, 2025, aims to highlight how ChemPass AI not only enhances the development process but also addresses pressing challenges in the industry.

ChemPass AI stands out for its ability to streamline the small molecule development cycle, drastically improving the success rates of new compounds while simultaneously reducing the time and costs associated with their development. This capability positions Evogene to lead in a highly competitive market, where the ability to rapidly innovate can determine a company's trajectory. By leveraging ChemPass AI, Evogene aims to foster product innovation through strategic partnerships and collaborations, as well as through its internal product pipelines. This holistic approach is designed to maximize the technology's potential and solidify Evogene's status as an industry leader.

In addition to the presentation, Haviv engages with potential investors through one-on-one meetings, furthering the company's outreach and relationship-building efforts. This initiative not only showcases Evogene's advancements but also opens avenues for collaboration and investment, crucial for scaling its innovative solutions. As the conference unfolds, Evogene continues to invite interested parties to connect with its Investor Relations team, reinforcing its commitment to transparency and engagement within the investment community.

Evogene's focus on its generative AI technology signifies a pivotal moment for the company as it strives to enhance productivity within the pharmaceutical and agricultural sectors. By integrating cutting-edge artificial intelligence into the development pipeline, Evogene is poised to lead transformative changes that could redefine industry standards. For more information about Evogene's initiatives and technological advancements, interested individuals can visit their website at www.evogene.com.

As Evogene prepares for its presentation, the company not only aims to showcase its innovations but also to highlight the significant role of AI in shaping the future of drug discovery and agricultural solutions. The emphasis on ChemPass AI reflects a broader trend of integrating advanced technologies into traditional sectors, promising enhanced efficiency and effectiveness in product development.